Related Experiment Videos
Q-switched ruby laser treatment of a congenital melanocytic nevus
1Beckman Laser Institute and Medical Clinic, Department of Surgery, University of California, Irvine, USA.
Background:
The treatment of medium-sized (1.5-20 cm diameter) congenital melanocytic nevi (CMN) has been the concern of dermatologists for decades. Although many techniques have been described and utilized, no single treatment has emerged as applicable under all circumstances.
Methods:
The Q-switched ruby laser (QSRL) at 694 nm, a wavelength well absorbed by melanin relative to other optically absorbing structures in skin, causes highly selective destruction of pigment-laden cells. In addition, the 20-nanosecond pulse duration produced by this laser approximates the thermal relaxation time for melanosomes, thereby confining the energy to the targeted cells.
Results:
In the present report, treatment using the QSRL resulted in complete clinical removal of a biopsy-documented medium-sized compound CMN with no recurrence after 5 years. In contrast to other therapeutic modalities, complications such has hypertrophic scarring, dyspigmentation, or atrophy were not observed.
Insights
The Q-switched ruby laser (QSRL) effectively removed medium-sized congenital melanocytic nevi (CMN) without recurrence or scarring. This laser treatment offers a safe and efficient option for CMN removal.
Area of Science:
- Dermatology
- Laser Medicine
- Aesthetic Surgery
Background:
- Congenital melanocytic nevi (CMN) present a long-standing therapeutic challenge for dermatologists.
- Existing treatments for medium-sized CMN (1.5-20 cm) lack universal applicability.
- The need for effective and safe treatment options for CMN persists.
Observation:
- The Q-switched ruby laser (QSRL) utilizes a 694 nm wavelength, which is highly absorbed by melanin.
- The laser's 20-nanosecond pulse duration targets melanosomes, minimizing collateral thermal damage.
- This selective photothermolysis targets pigment-laden cells with precision.
Findings:
- Complete clinical removal of a biopsy-documented medium-sized compound CMN was achieved using the QSRL.
- No recurrence of the CMN was observed after a 5-year follow-up period.
- The treatment avoided common complications such as hypertrophic scarring, dyspigmentation, and atrophy.
Implications:
- The QSRL presents a promising therapeutic modality for treating medium-sized congenital melanocytic nevi.
- This laser treatment may offer a superior safety and efficacy profile compared to conventional methods.
- Further research into QSRL for CMN treatment could refine clinical protocols and expand patient options.